MeiraGTx (MGTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
11 Jun, 2026Opening remarks and agenda
Meeting commenced with introductions of board members, executive officers, and the independent auditor.
Agenda and rules of conduct were outlined, with instructions for shareholder participation and Q&A.
Record date for voting was set as April 21, 2026, and notice of meeting was confirmed as distributed.
Board and executive committee updates
Board members and executive officers were introduced, including the CEO, CFO/COO, and General Counsel.
Shareholder proposals
Two proposals were presented: election of three Class 2 directors and ratification of the independent auditor.
Shareholders were invited to submit questions on the proposals before voting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from MeiraGTx
- Late-stage pipeline, transformative gene therapies, and strong partnerships drive near-term approvals.MGTX
Corporate presentation - Q2 2026 net income of $160.7M on $321.4M revenue, fueled by licensing, acquisitions, and clinical progress.MGTXQ2 2026
- Late-stage gene therapies advance with pivotal xerostomia data, XLRP filings, and major partnerships.MGTXJefferies Global Healthcare Conference 2026
- Late-stage pipeline and riboswitch platform drive transformative therapies for major unmet needs.MGTXCorporate presentation
- Regained RPGR rights and late-stage pipeline progress position for near-term commercialization.MGTXBank of America Global Healthcare Conference 2026
- Q1 2026 net loss rose to $46.3M; FDA breakthrough, bota-vec deal, and $100M raise drive pipeline.MGTXQ1 2026
- Director elections, auditor ratification, and robust governance highlight this year's proxy.MGTXProxy filing
- Director elections and auditor ratification headline the June 2026 annual meeting agenda.MGTXProxy filing
- Gene therapy restored vision and quality of life in all 11 LCA4 children, with lasting benefit.MGTXStudy Update